Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARVN vs ALEC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALEC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

ALEC Overall Winner 6-Pillar Tally: ARVN 2 – 4 ALEC Matrix Metrics: ARVN 3 – 7 ALEC

As of Nov 16, 2026, Alector, Inc. (ALEC) is the stronger overall head-to-head candidate over Arvinas, Inc (ARVN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). ARVN carries a Unified Composite Score of 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin), whereas ALEC carries 37.0/100 (SELL) at $2.54 (8.5x Forward P/E, 21.8% operating margin).

  • Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. ALEC 37.0/100 SELL), ALEC captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.8% vs. -10.1% operating margin) and revenue trajectory (+4895.9% vs. -98.8% YoY).
  • Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile ALEC trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARVN vs ALEC
ARVN NASDAQ
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57
ALEC NASDAQ Head-to-Head Winner
Alector, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.54
+0.2% 1D
Market Cap $364.7M
TTM Revenue $173M
Forward P/E 8.5x
Beta / 30D Vol 1.58β · 95% Vol
Unified Composite Score
37.0 / 100 SELL
Tech 50.0 Fund 34.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 62.3 · SMA20: $2.21 · SMA50: $2.07

6-Pillar Scorecard Institutional Category Breakdown (ARVN 2 – 4 ALEC)

Columns: Metric · ARVN · ALEC
1. Valuation Multiples ALEC
Forward P/E 17.9x 8.5x
Trailing P/E 17.9x 6.6x
PEG Ratio N/M N/M
EV / Revenue 1.3x 1.8x
2. Growth & Scale ARVN
Revenue Growth (YoY) -98.8% +4895.9%
Earnings Growth (YoY) +0.0% -86.3%
TTM Revenue (USD) $275M $173M
Market Cap $449.9M $364.7M
3. Profitability & Quality ALEC
Gross Margin 96.7% 42.5%
Operating Margin -10.1% 21.8%
Net Profit Margin -3.5% 23.9%
Return on Equity (ROE) -1.8% 47.5%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$160M -$150M
Cash Flow Margin -58.0% -86.5%
Net Cash / Leverage $81M Net Cash $54M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALEC
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 108.7% (25th %ile) 77.3% (9th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat ALEC
OpEx & R&D Intensity N/A 20.7% of Rev ($36M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARVN (3) vs ALEC (7)
Institutional Metric ARVN ALEC Criterion Row Edge
Market Capitalization
Scale
$449.9M $364.7M Larger Scale ARVN
Trailing P/E Ratio
Valuation
17.9x 6.6x Lower Multiple ALEC
Forward P/E Ratio
Valuation
17.9x 8.5x Lower Multiple ALEC
Revenue Growth (YoY)
Growth
-98.8% +4895.9% Higher Growth ALEC
Operating Margin (TTM)
Profitability
-10.1% 21.8% Higher Margin ALEC
Net Profit Margin
Profitability
-3.5% 23.9% Higher Margin ALEC
Return on Equity (ROE)
Capital Efficiency
-1.8% 47.5% Higher ROE ALEC
52-Week Range Position
Momentum
5% ($6–$15) 83% ($1–$3) Stronger Trend ALEC
Beta / 30D Volatility
Risk Regime
1.40β · 66% Vol 1.58β · 95% Vol Lower Realized Risk ARVN
Unified Institutional Score
Composite Signal
52.9 / 100 (HOLD) 37.0 / 100 (SELL) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
$275M $173M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
96.7% 42.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($81M Net Cash) -$150M ($54M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ALEC +41.62 pp
ARVN: -3.3% · ALEC: +38.32%
3M Horizon ALEC +42.37 pp
ARVN: -27.21% · ALEC: +15.16%
6M Horizon ALEC +43.28 pp
ARVN: -23.23% · ALEC: +20.05%
1Y Horizon ALEC +145.48 pp
ARVN: -33.4% · ALEC: +112.08%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARVN Revenue ALEC Revenue ARVN Op. Margin ALEC Op. Margin Margin Leader
FY2018 $10M $30M -306.3% -208.3% ALEC
FY2019 $20M $20M -281.4% -539.2% ARVN
FY2020 $20M $20M -554.1% -925.1% ARVN
FY2021 $50M $210M -403.4% -18.0% ALEC
FY2022 $130M $130M -200.3% -103.2% ALEC
FY2023 $80M $100M -511.5% -156.3% ALEC
FY2024 $260M $100M -95.0% -144.2% ARVN
FY2025 $260M $20M -45.1% -741.3% ARVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALEC CONSOLIDATION
52d in phase · OBV ACCUMULATION
Current IV 77.3%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ALEC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ALEC Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $364.7M market capitalization and 21.8% operating margin.
OpEx & R&D Reinvestment 20.7% of Rev ($36M)
90D Engineering Disclosures 0 Published

Investor FAQ ARVN vs ALEC Key Questions & Quantitative Answers

As of Nov 16, 2026, Alector, Inc. (ALEC) is the stronger overall head-to-head candidate over Arvinas, Inc (ARVN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). ARVN carries a Unified Composite Score of 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin), whereas ALEC carries 37.0/100 (SELL) at $2.54 (8.5x Forward P/E, 21.8% operating margin). Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. ALEC 37.0/100 SELL), ALEC captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.8% vs. -10.1% operating margin) and revenue trajectory (+4895.9% vs. -98.8% YoY). Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile ALEC trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARVN leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with ALEC at +4895.9% YoY revenue growth and -86.3% YoY earnings growth on $173M TTM revenue (42.5% gross margin, 21.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARVN cumulative revenue shifted +2500.0% while ALEC shifted -33.3%. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus 20.7% of Rev ($36M) (0 disclosures) for ALEC.

ALEC screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas ALEC trades at 8.5x Forward P/E, 6.6x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-86.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus ALEC (47.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, ALEC carries 77.3% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.58β · 95% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.